IMMUNIC, INC. financial data

Symbol
IMUX on Nasdaq
Location
New York, United States
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 150% % -55%
Debt-to-equity 184% % 333%
Return On Equity -716% % -302%
Return On Assets -252% % -101%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 120,284,724 shares 34%
Common Stock, Shares, Outstanding 98,650,590 shares 9.5%
Entity Public Float $100,000,000 USD -8.7%
Common Stock, Value, Issued $9,000 USD 12%
Weighted Average Number of Shares Outstanding, Basic 193,897,764 shares 91%
Weighted Average Number of Shares Outstanding, Diluted 193,897,764 shares 91%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $84,531,000 USD 8.8%
General and Administrative Expense $21,001,000 USD 16%
Operating Income (Loss) $105,532,000 USD -10%
Nonoperating Income (Expense) $2,485,000 USD -70%
Net Income (Loss) Attributable to Parent $103,047,000 USD -6.3%
Earnings Per Share, Basic 0 USD/shares 33%
Earnings Per Share, Diluted 0 USD/shares 33%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $35,132,000 USD -41%
Other Assets, Current $818,000 USD 8.1%
Assets, Current $39,273,000 USD -38%
Property, Plant and Equipment, Net $640,000 USD 3.6%
Operating Lease, Right-of-Use Asset $791,000 USD -9.9%
Assets $40,704,000 USD -37%
Accounts Payable, Current $7,918,000 USD 31%
Accrued Liabilities, Current $19,454,000 USD 20%
Liabilities, Current $30,079,000 USD 29%
Operating Lease, Liability, Noncurrent $126,000 USD -32%
Liabilities $30,205,000 USD 28%
Accumulated Other Comprehensive Income (Loss), Net of Tax $2,582,000 USD -34%
Retained Earnings (Accumulated Deficit) $589,271,000 USD -21%
Stockholders' Equity Attributable to Parent $10,499,000 USD -75%
Liabilities and Equity $40,704,000 USD -37%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $21,776,000 USD 9.1%
Net Cash Provided by (Used in) Financing Activities $0 USD -100%
Net Cash Provided by (Used in) Investing Activities $47,000 USD -52%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 98,650,590 shares 9.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $21,364,000 USD -142%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $35,132,000 USD -41%
Deferred Tax Assets, Valuation Allowance $117,078,000 USD 18%
Deferred Tax Assets, Gross $117,078,000 USD 18%
Operating Lease, Liability $792,000 USD -12%
Depreciation $42,000 USD 24%
Payments to Acquire Property, Plant, and Equipment $47,000 USD 52%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $104,351,000 USD -7.7%
Lessee, Operating Lease, Liability, to be Paid $832,000 USD -12%
Operating Lease, Liability, Current $666,000 USD -6.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two $87,000 USD 12%
Lessee, Operating Lease, Liability, to be Paid, Year One $449,000 USD 3.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $40,000 USD -17%
Lessee, Operating Lease, Liability, to be Paid, Year Three $84,000 USD 2.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $0 USD -100%
Additional Paid in Capital $597,179,000 USD 14%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $43,000 USD 65%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%